GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes
- 513 Downloads
Prostate cancer (PC) is very common in developed countries. However, the molecular determinants of PC metastasis are unclear. Previously, we reported that germline variation influences metastasis in the C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP) mouse model of PC. These mice develop prostate tumors similar to a subset of poor outcome, treatment-associated human PC tumors. Here, we used TRAMP mice to nominate candidate genes and validate their role in aggressive human PC in PC datasets and cell lines. Candidate metastasis susceptibility genes were identified through quantitative trait locus (QTL) mapping in 201 (TRAMP × PWK/PhJ) F2 males. Two metastasis-associated QTLs were identified; one on chromosome 12 (LOD = 5.86), and one on chromosome 14 (LOD = 4.41). Correlation analysis using microarray data from (TRAMP × PWK/PhJ) F2 prostate tumors identified 35 metastasis-associated transcripts within the two loci. The role of these genes in susceptibility to aggressive human PC was determined through in silico analysis using multiple datasets. First, analysis of candidate gene expression in two human PC datasets demonstrated that five candidate genes were associated with an increased risk of aggressive disease and lower disease-free survival. Second, four of these genes (GNL3, MAT1A, SKA3, and ZMYM5) harbored SNPs associated with aggressive tumorigenesis in the PLCO/CGEMS GWAS of 1172 PC patients. Finally, over-expression of GNL3 and SKA3 in the PC-3 human PC cell line decreased in vitro cell migration and invasion. This novel approach demonstrates how mouse models can be used to identify metastasis susceptibility genes, and gives new insight into the molecular mechanisms of fatal PC.
KeywordsProstate cancer Metastasis Mouse models TRAMP Genetic susceptibility
Androgen deprivation therapy
Quantitative trait loci
Logarithm of odds score
Single nucleotide polymorphism
Genome-wide association study
Distant metastasis-free survival
This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov). This research was supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health [HG200366-05].
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: A Cancer J Clin 65(1):5–29Google Scholar
- 8.Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J (2014) Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. doi: 10.1200/JCO.2013.54.3553 Google Scholar
- 15.Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A (2008) Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 172(1):236–246PubMedCentralCrossRefPubMedGoogle Scholar
- 20.Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED (2001) The TRAMP mouse as a model for prostate cancer. Current protocols in immunology/edited by John E Coligan [et al] Chapter 20:Unit 20 25Google Scholar
- 27.Dudoit S, van der Laan MJ, Pollard KS (2004) Multiple testing. Part I. Single-step procedures for control of general type I error rates. Stat Appl Genet Mol Biol 3(1):1–69Google Scholar
- 31.Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate LC, Ovarian Cancer Screening Trial Project T (2000) The prostate, lung, colorectal and ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21(6 Suppl):251S–272SCrossRefPubMedGoogle Scholar